Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643247
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-11
Brief Title:
Electroacupuncture Regulation of Immune Cells in Herpes Zoster
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Regulatory Mechanisms of Electroacupuncture Intervention on Immune Cells in Herpes Zoster
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Herpes Zoster HZ caused by the Varicella-Zoster Virus VZV is a common infection characterized by localized pain and blistering with higher incidence in females HZ affects patients physical health mental well-being and quality of life The immune system is critical in HZ pathogenesis Studies show acupuncture relieves pain modulates immunity and may lower postherpetic neuralgia PHN risk However evidence is limited on whether electroacupuncture EA alleviates HZ by modulating immune cells Using mass cytometry CyTOF this study will analyze peripheral immune cell changes pre- and post-EA to explore its regulatory effects on HZ immunity This study will recruit HZ patients and healthy controls HC dividing patients into medication-only and medicationEA groups to assess EAs potential immunomodulatory effects in HZ treatment
Detailed Description:
The study will enroll 8 HZ patients who meet the inclusion criteria and 3 age- and gender-matched healthy controls HC HZ patients will be randomly assigned in a 11 ratio to a medication-only group or a medication plus electroacupuncture group All participants will receive Valacyclovir Hydrochloride tablets and Mecobalamin tablets HZ-related immune cells in peripheral blood will be analyzed using CyTOF before treatment day 0 during treatment day 4 and after treatment day 7 Pain intensity and characteristics will be assessed using the Visual Analogue Scale VAS and the Douleur Neuropathique 4 DN4 questionnaire Lesion healing time to vesicle cessation crusting and scab detachment and adverse events will also be recorded to evaluate lesion regression in HZ patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None